If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() British Journal of Clinical PharmacologyVolume 57 Issue 4, Pages 402 - 411 Published Online: 14 Nov 2003 Journal compilation © 2010 The British Pharmacological Society The Journal of The British Pharmacological Society
Abstract | References | Full Text: HTML, PDF (Size: 268K) | Related Articles | Citation Tracking Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years Copyright 2003 Blackwell Publishing Ltd KEYWORDS antihistamine • cetirizine • paediatric population pharmacokinetics ABSTRACTAims To evaluate retrospectively the population pharmacokinetics of cetirizine, a second-generation antihistamine, in children. Methods Data were pooled from six clinical trials, in which cetirizine was administered orally in various formulations and in single and multiple dosage regimens. The population consisted of 112 children (33 female and 79 male) aged 6 months to 12 years. A one-compartment open model with first-order absorption and elimination was fitted to the plasma concentration-time profiles using nonlinear mixed effects modelling with first-order estimation. Results A linear association was found between apparent clearance (CL/F) and age with the former increasing by 0.12 l h Conclusions Population analysis predicts a linear increase in cetirizine CL/F and V/F with age, with CL/F being slightly lower in female children, relative to males of the same age. However, this gender difference probably has no clinical consequences. Since V/F increased more rapidly with age than CL/F, a nonlinear increase in half-life was seen, from < 4 h in infants to near the adult value at 12 years of age. The current recommended dosing regimens that younger children should receive lower but more frequent doses, are confirmed by the present analysis. Received 9 June 2003, accepted 12 September 2003. |